Promoting coagulation and activating SMAD3 phosphorylation in wound healing via a dual-release thrombin-hydrogel

Chongyang Wang,Tianyi Wu,Guangwang Liu,Ruoyu Cheng,Jian Fei,Xinping Song,Yimin Chai,Cunyi Fan,Xudong Liu,Wenguo Cui,Shen Liu

DOI: https://doi.org/10.1016/j.cej.2020.125414

IF: 15.1

2020-10-01

Chemical Engineering Journal

Abstract:<p>In recent years, researchers have combined various drugs to target different phases of impaired diabetic wound healing. Often, in such cases, the drug that aims to regulate the early phases may be released in the later healing processes, or the drug intended to activate the later processes may be released in the early phases; this can lead to side effects. Therefore, a one-drug delivery system that can modulate multiple phases of wound healing is expected to provide a new alternative treatment. In the present study, we simultaneously incorporated free thrombin (Th) and Th-loaded liposomes (Th-Lipo) into a photocrosslinkable gelatin derivative (GelMA) hydrogel (Th/) to achieve an initially sufficient release of Th to promote blood coagulation and long-lasting release to modulate the later processes of wound healing. For materials fabrication, hydrogen bonding between liposome phospho-lipid bilayers and GelMA polymer chains was used to prolong the release period of Th and to enhance the mechanical properties of hydrogel. In vitro, we demonstrated that Th could improve the impaired cell function of fibroblasts and endothelial cells in a high glucose medium. In vivo, the Th/ showed great efficacy in promoting blood coagulation, accelerating wound healing through enhancing wound closure, angiogenesis, and collagen synthesis. An in vivo mechanism study further revealed that Th mediates phosphorylation of SMAD3 (Ser204), which plays a key role in accelerating wound healing. This study provides a new biomaterial to promote diabetic cutaneous wound healing.</p>

engineering, chemical, environmental

What problem does this paper attempt to address?

The paper aims to address multiple issues in diabetic wound healing, particularly in the context of large-area skin defects caused by acute trauma. Specifically, the paper attempts to regulate different stages of wound healing by developing a novel drug delivery system to improve skin wound healing in diabetic patients. The main objectives include:

1. **Precise Regulation of Multiple Healing Stages**: By designing a photo-crosslinked gelatin derivative (GelMA) hydrogel (Th/Th-Lipo@Gel) capable of simultaneously releasing thrombin (Th) and its liposomal form (Th-Lipo), the study aims to achieve rapid hemostasis in the early stage and sustained healing effects in the later stage.

2. **Improvement of Cellular Dysfunction**: The study found that the functions of fibroblasts and endothelial cells are impaired in a high-glucose environment. Thrombin can improve the functions of these cells under high-glucose conditions, thereby promoting angiogenesis, collagen synthesis, and other healing processes.

3. **Precise Control of Drug Release**: By incorporating thrombin and liposomes into the GelMA hydrogel, the study enhances the mechanical properties of the hydrogel through hydrogen bonding and extends the release time of thrombin, ensuring a combination of early burst release and long-term sustained release.

4. **In Vivo Efficacy Verification**: By establishing a diabetic rat model, the study evaluates the effects of the composite hydrogel in promoting wound healing, accelerating angiogenesis, and collagen deposition, and further explores its mechanisms of action.

In summary, the study proposes a new biomaterial—GelMA hydrogel with dual-release thrombin—for promoting skin wound healing in diabetic patients and validates its efficacy and potential mechanisms through in vitro and in vivo experiments.